The Board of directors exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under the incentive programme

Report this content

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi™) on 4 May 2021, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the Annual General Meeting – on a directed share issue of no more than 3,298,984 redeemable and convertible class C shares.

The meeting also resolved to authorise the Board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorisation may be made on one or several occasions until the Annual General Meeting 2022 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share.

The Board of directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 21 July – 4 November 2021.

The company currently holds 8,670,882 own common shares and no own class C shares. Subsequently to the effected repurchase of class C shares above, all repurchased class C shares are intended to be converted to common shares, where after the number of own common shares will amount to 11,969,866.

About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and Asia. In 2020, Sobi’s revenue amounted to SEK 15.3 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at

For more information, please contact

Paula Treutiger, Head of Communication & Investor Relations
+46 733 666 599

Maria Kruse, Corporate Communication & Investor Relations
+46 767 248 830

The information was released for public distribution on 20 July 2021 at 19:00 CEST.

Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00